The invention discloses a schizophrenia biomarker combination based on intestinal flora and application. Whether candidate medicines can be used for treating or preventing schizophrenia or not can be determined by utilizing the influences of the candidate medicines on the biomarker before and after use. The defects that an existing schizophrenia diagnosis method cannot achieve early-stage pre-warning, cannot predict the pathogenesis and development tendency of schizophrenia and the like. Therefore, the schizophrenia biomarker combination can be applied to predicting the pathogenesis and development tendency of schizophrenia and applied to preparation and application of a kit for disease pathological typing.
Schizophrenia biomarker combination based on intestinal flora and application and screening thereof